Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene OK'd to Test PARP Inhibitor in China

publication date: Aug 19, 2016
BeiGene, a Beijing oncology biopharma, received approval from the CFDA to begin China trials of BGB-290, a PARP1/2 inhibitor. Trials of BGB-290 are already underway in Australia and the US. BeiGene believes BGB-290 will prove to be a more selective inhibitor of PARP 1/2 than its competitors, decreasing the side effects and increasing efficacy, in patients with solid tumors. BeiGene also pointed out that BGB-290 is the third of the company's programs to be approved for China trials. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital